Obtaining Samples from Human Subjects to Facilitate Basic, Translational and Clinical Research

点击翻译按钮获取中文摘要

This protocol defines in general terms the purposes for which blood, urine and ultrafiltrate will be collected from adult research subjects and healthy volunteers by members of the NIH Clinical Center's Critical Care Medicine Department and collaborating institutions and establishes general conditions under which sampling will be performed. Blood drawing will be consistent with NIH Clinical Center guidelines. The Critical Care Medicine Department and our associated investigators are involved in the development of new translational research protocols and maintenance of existing IRB approved research protocols. This protocol will support the establishment of new translational research protocols through assay development and provide information to guide the effective implementation of new protocols as well as maintain efficiency in operations of existing protocols. The protocol was approved by the National Heart, Lung, and Blood Institutional Review Board (recently changed to General Medicine 1 IRB) in August 2017. Over the course of the protocol, research subjects have provided blood samples for inflammatory marker studies, to characterize low density granulocytes as a novel therapeutic target for patients with sepsis, DNA gene sequencing for Pulmonary Arterial Hypertension (PAH), immunophenotyping for relapsing polychondritis, isolation of B cells for flow cytometry, cell free DNA isolation for PAH, thrombelastography (TEG) and other blood markers of coagulation and fibrinolysis, RNA isolation for sequencing, vitamin C levels, PBMCs isolated from whole blood for reprogramming and generation of induced pluripotent stem cell (iPSC) lines, and to isolate cells and plasma to either 1) serve as a comparator for COVID-19 patients or 2) perform in-vitro stimulations to study several COVID-19 molecular mechanisms. During the current reporting period 12 subjects were newly enrolled (9 healthy volunteers and 3 patients). Over the life of the protocol (as of September 2023) a total of 114 subjects have enrolled (65 healthy volunteers and 49 patients). Over the current reporting period 189 blood samples were provided to investigators and over the life of the protocol 677 samples have been provided to investigators. The following abstract have been presented using samples obtained from this protocol. Brusca SB, Elinoff JM, Jang MK, Demirkale CY, Valantine HA, Solomon MA, and Agbor-Enoh ST. Plasma Cell-free DNA as a Novel Marker of Disease Severity in Pulmonary Arterial Hypertension. American College of Cardiology 68thAnnual Scientific Session, J Am Coll Cardiol, 73(9, S1): S1897, 2019. Lu M, Blaine K, Cullinane A, Hall C, Dulau-Florea ,A, Sun J, Chenwi H, Graninger G, Harper B, Elinoff JM, and Solomon MA. Pulmonary Arterial Hypertension Patients Display Normal Kinetics of Clot Formation. American Heart Association Scientific Sessions, 140: A10714, 2019 Becicka W, Garrad E, Berreby G, Wang J, Nghiem K, Ramos-Benitez M, Cowling B, Moitra J, Huffstutler R, Carney K, Ferrante E, Cudrici C, Brofferio A, Tourdot B, Jacobson K, Knight J, Kanthi Y, and Boehm M. Genetic Deficiency of the Ectoenzyme CD73 Increases Neutrophil Extracellular Trap Formation in Patients with ACDC. Arteriosclerosis, Thrombosis, and Vascular Biology: Vascular Discovery Conference 2022 Becicka W, Berreby G, Wang J, Moitra J, Panicker S, Tourdot BE, Norris P, Kelly K, Zuo Y, Dumont L, Solomon MA, Knight JS and Kanthi Y. Antiphospholipid antibodies in COVID-19 Convalescent Plasma. Arteriosclerosis, Thrombosis, and Vascular Biology: AHA Vascular Discovery Conference 2022 Strich J, Chertow D, Ramos-Benitez, Marcos, and Warner S. SYK Inhibition Abrogates Neutrophil Hyperactivation in Response to Lipopolysaccharides. Critical Care Medicine, 51(1): 562, 2023. The following papers have been published using samples obtained from this protocol. Lu M, Blaine KP, Cuillinane A, Hall C, Dulau-Florea A, Sun J, Graninger GM, Harper BJ, Brusca SB, Elinoff JM, and Solomon MA. Pulmonary Arterial Hypertension Patients Display Normal Kinetics of Clot Formation. Pulm Circ, 11(3): 1-9, 2021 Strich RJ, Ramos-Benitez MJ, Randazzo D, Stein SR, Babyak A, Davey RT, Suffredini AF, Childs RW, Chertow DS. Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic. The Journal of Infectious Diseases, 223 (6): 981984, 2021. Perez-Valencia LJ, Vannella KM, Ramos-Benitez MJ, Sun J, Abu-Asab M, Dorward DW, Awad KS, Platt A, Jacobson E, Kindrachuk J, Chertow DS (2023). Ebola virus shed glycoprotein is toxic to human T, B, and natural killer lymphocytes. iScience 26, 107323. https://doi.org/10.1016/j.isci.2023.107323